SynthesisBMC immunology2026
IL-23 serum levels and IL23R polymorphisms in psoriasis: a meta-analysis of susceptibility and severity.
Synthesis in BMC immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Real-World Effectiveness and Safety of Tildrakizumab in a Large Spanish Multicenter Cohort from Spanish Psoriasis Group (GPS).Pharmacy (Basel, Switzerland) · 2026Article
- Genetic Association Study ofLife (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPsoriasis is an immune-mediated inflammatory disease with a strong genetic basis. The Interleukin-23 (IL-23)/Th17 axis is central to its pathogenesis. While IL-23 is established, studies on systemic serum levels and IL23R gene polymorphisms yielded varied results. Our study clarified these associations through a systematic review and meta-analysis.
methodsA systematic search was performed to find relevant studies. For serum IL-23, a random-effects model calculated overall Hedges’s g. For polymorphisms, pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated for allelic, dominant, and recessive models. Heterogeneity (I² statistic) and sensitivity analyses were performed.
resultsMeta-analysis of serum IL-23 levels (six studies) showed no significant difference between patients and controls (Hedges’s g = -0.48, 95% CI: -1.58 to 0.62) with high heterogeneity (I² = 96.34%). For polymorphisms, the rs11209026 A allele showed a significant protective effect (OR = 0.52, p = 0.002). Conversely, rs2201841 increased psoriasis risk (OR = 1.39, p = 0.001), as did rs7530511 under the recessive model (OR = 1.29, p = 0.014). Significant associations were found between polymorphisms and both psoriasis severity (p < 0.001) and clinical type (p < 0.001).
conclusionOur meta-analysis confirms a significant association between IL23R polymorphisms and susceptibility to psoriasis, with rs11209026 being protective and rs2201841 conferring risk. However, data does not support serum IL-23 as a reliable biomarker. This study widens the view toward personalized medicine and using polymorphisms as prognostic models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.